In The News
MedPage Today – Bone Marrow Biopsy Value Limited in Follicular Lymphoma Response Assessment
Bone marrow biopsy (BMB) provided little information for response assessment in clinical trials of follicular lymphoma (FL) and should be eliminated from clinical trial requirements
Regulatory Focus – Drugmakers seek details on use of ctDNA as a biomarker or early endpoint
Drug developers are asking the US Food and Drug Administration (FDA) for more details on definitions, methodologies, and use cases for employing circulating tumor DNA
OncLive – Expanding Opportunities for Real-World Evidence in Oncology
As the therapeutic paradigm for oncology moves toward targeted therapies, drug development has also undergone a shift toward advancing precision medicine in specific patient populations.
PR Newswire – Manuscript for Improving Cancer Scientist and Patient Advocate Relationships Published
Theresa’s Research Foundation is excited to announce a new manuscript titled “Improving the Odds Together: A Framework for Breast Cancer Research Scientists to Include Patient Advocates
The Washington Post – The Pandemic Is Waning. Anthony Fauci Has a Few More Lessons to Share.
You gotta f—ing suck it up,” Anthony Fauci tells me from the deck of his home in Washington, D.C., overlooking a small pool that takes
HealthLeaders Media – By Reducing Barriers, DCTs Improve Patient Access to Oncology Trials
The 2022 ASCO meeting kicked off in the first week in June, inspiring many discussions throughout the following weeks about new and exciting innovations in
Medscape – FDA Okays Cancer Drugs Faster Than EMA. But at What Cost?
Over the past decade, the US Food and Drug Administration (FDA) has approved new cancer drugs twice as fast as the European Medicines Agency (EMA),
Springer Link – Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-Making
Introduction Acute myeloid leukemia (AML) is one of the more common blood cancers, characterized by peripheral blood and bone marrow myeloblast proliferation, leading to bone
Regulatory Focus – This Week at FDA: User fee moves, COVID vaccine updates, and more
Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device
Statement on the VALID Act of 2022
Friends of Cancer Research (Friends) applauds the thoughtful work in constructing the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2022 – and particularly for including
